Revolutionary technology that detects and disrupts blood clots without the side effects of traditional anticoagulants
Blood clots are a silent epidemic affecting millions worldwide
Thrombosis is responsible for 1 in 4 deaths globally, making it one of the most critical health challenges of our time.
More than 40 million acute thrombotic events occur each year, causing strokes, heart attacks, and pulmonary embolisms.
Countless patients live with chronic thrombotic conditions requiring daily medication and lifestyle restrictions.
Traditional anticoagulants prevent clots but cause dangerous bleeding side effects and require constant monitoring.
NanoMax nanorobots intelligently target only pathological clots, leaving protective clots intact
Each NanoMax nanorobot is equipped with advanced computational logic that enables it to make real-time decisions in the bloodstream. Our proprietary algorithms allow the nanorobot to distinguish between healthy blood components and potential threats.
NanoMax nanorobots continuously scan for pathological blood clots while ignoring protective clots that are essential for wound healing. Using advanced biosensors, they identify dangerous clots by analyzing molecular markers, size, location, and formation patterns.
Once a pathological clot is detected, NanoMax nanorobots initiate precise mechanical disruption of the dangerous clot only. This targeted approach eliminates the clot without affecting healthy blood flow or beneficial clotting mechanisms, resulting in zero bleeding side effects.
Eliminates the dangerous bleeding side effects of traditional anticoagulants
Only disrupts pathological clots, leaving protective mechanisms intact
24/7 monitoring and immediate response to emerging clots
No dietary restrictions or constant monitoring required
Be part of the revolution in thrombosis prevention. Leave your contact information to stay updated on our progress.
NanoMax is currently in early stage development. Join our community to get exclusive updates on our clinical trials and product launch.